

018813/027 8799



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Madison, et al.)	<u>Certificate of Mailing by Express Mailing</u>
)	<u>Under 37 C.F.R. § 1.10</u>
Serial No.	09/657,986)	I hereby certify that this paper and the
)	attached papers are being deposited with
Filed:	September 8, 2000)	the United States Postal Service by
)	Express Mail, Express Mailing Label No.
)	US in an envelope
For:	INHIBITORS OF SERINE)	addressed to:
	PROTEASE ACTIVITY OF)	Commissioner for Patents
	MATRIPTASE)	P.O. Box 1450
Art Unit:	1652)	Alexandria, VA 22313-1450, on this date
Examiner:	Walicka, Malgorzata A.)	_____ 2003
)	Patricia Muñoz

DECLARATION OF EDWIN L. MADISON
PURSUANT TO 37 C.F.R. § 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Edwin L. Madison, declare as follows:

1. I am presently Vice President of Biological Research of Dendreon Corporation and Dendreon San Diego, LLC. From December 2000 until July 29, 2003, when Corvas International was acquired by Dendreon, I was Vice President of Biological Research at Corvas International. I joined Corvas in 1998 and previously served first as Director, Molecular Biology. I subsequently served as Senior Director of Molecular Biology and then as Executive Director of Biological Research. Prior to joining Corvas, I was Associate Professor of Vascular Biology at the Scripps Research Institute. A copy of my curriculum vitae is attached as Exhibit A.

018813/027 8799

2. I am an inventor of the subject matter described and claimed in the above-identified United States Patent Application United States Serial No. 09/657,986.

3. I have reviewed the above-identified United States Patent Application, U.S.S.N. 09/657,986, as filed, and its claims, as presently pending. In particular, I have reviewed Example A, "Amidolytic Assay for Determining Inhibition of Serine Protease Activity of Matriptase or MTSP1".

4. Following the method for the assay as described in Example A of the above-identified application, a number of the compounds whose use as an inhibitor of matriptase or membrane-type serine protease 1 ("MTSP1") is described and claimed in the present application were tested for their activity to inhibit matriptase or MTSP1.














5. Exhibit B, attached hereto, lists certain compounds and their IC_{50} 's for inhibition of matriptase or MTSP1 obtained using the assay described in Example A. The compounds listed in Exhibit B are described and claimed in the above-identified United States Patent Application as inhibitors of matriptase or MTSP1.











I declare under penalty of perjury that the foregoing statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code §1001, and that such willful false statements

018813/027 8799

may jeopardize the validity of the patent. Executed this 21st
day of November, 2003.

Edwin L. Madison
EDWIN L. MADISON

#	cvs number	MOLSTRUCTURE	MATRIP IC50 (30 MIN.)
10	01473		34.7
16	01641		2.21
17	01795		2.7
2	01874		4.3
1	03044		1.65
5	03099		9.3
6	03143		9.3
21	03262		2.3
11	03101		33.1
18	03124		9.6
20	03183		3.4
15	01376		1
8	02551		17.1

9	02890		19.8
7	03051		9.9
12	03173		74.2
4	03130		8.5
22	03315		295
23	03335		165
3	03496		8.2
13	03035		152
14	02907		276
19	03174		6